1350 S. LOOP ROAD, ALAMEDA, CA
Material Contracts, Other Events
Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Investor Presentation
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Announces Pricing of Common Stock Offering
Provides Business Update and Reports Third Quarter 2025 Financial Results
Q1
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
SEC Form 25 - Delisting Notification
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload